Cargando…
Bioequivalence and Safety Assessment of Two Formulations of Metformin Hydrochloride Sustained-Release Tablets (Yuantang(®) SR and Glucophage(®) XR) Under Fed Conditions in Healthy Chinese Adult Subjects: An Open-Label, Two-Way Crossover, Sequence Randomized Phase I Clinical Trial
OBJECTIVE: The purpose of this single-center, randomized, open, two-period, two-sequence crossover, single-dose administration, bioequivalence research was to evaluate the bioequivalence and safety of the generic formulations of metformin hydrochloride sustained-release (MH-SR) 500 mg tablets (test...
Autores principales: | Sun, Ming-Li, Liu, Hui-Juan, Luo, Xiang-Dong, Wang, Yu, Zhang, Wei, Liu, Chen, Wang, Xinghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885941/ https://www.ncbi.nlm.nih.gov/pubmed/35061235 http://dx.doi.org/10.1007/s40268-021-00377-w |
Ejemplares similares
-
Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke(®) and Glucophage(®)-XR) in healthy Chinese volunteers: a randomized phase I clinical trial
por: Sun, Ming-Li, et al.
Publicado: (2022) -
Chinese- and French-Manufactured Immediate-Release Glucophage(®) Bioequivalence: A Randomized, Open-Label, Crossover Study
por: Hu, Chaoying, et al.
Publicado: (2022) -
Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study
por: Shi, Ping, et al.
Publicado: (2021) -
Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus
por: Guo, Li-xin, et al.
Publicado: (2021) -
Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial
por: Li, Yinjuan, et al.
Publicado: (2020)